吉非替尼治疗晚期非小细胞肺癌脑转移的疗效  

Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis

作　　者：吴驰[1] 李龙芸[1] 王孟昭[1] 张力[1] 张晓彤[1] 钟巍[1] 王树兰[1] 王华竹[1] 

机构地区：[1]中国协和医科大学中国医学科学院北京协和医院呼吸内科

出　　处：《中华肿瘤杂志》2007年第12期943-945,共3页Chinese Journal of Oncology

摘　　要：目的探讨吉非替尼治疗非小细胞肺癌(NSCLC)脑转移的疗效及其对预后的影响。方法44例NSCLC脑转移患者中,接受过全脑放疗者30例,接受过化疗者42例,均在入组前1个月结束治疗。入组者口服吉非替尼250 mg,每日1次,服药至疾病进展或死亡。服药后定期复查。结果吉非替尼治疗的有效率为31.8%,稳定率为47.7%,临床获益率为79.5%。中位无进展生存时间为9个月,中位总生存时间为13个月。吉非替尼对颅内转移灶的控制率达81.9%。既往接受全脑放疗患者与未接受全脑放疗者相比,其转移灶控制率差异无统计学意义(P=0.566)。结论吉非替尼治疗NSCLC脑转移的疗效显著,不良反应轻微,能明显改善患者预后,是晚期NSCLC患者的治疗方法之一。Objective Brain metastasis is frequently found in patient with advanced non-small cell lung cancer. Cefitinib is a inhibitor of epidermal growth factor receptor and can be used for the treatment of advanced non-small cell lung cancer （NSCLC）. The aim of this study was to evaluate the antitumor efficacy of Cefitinib in advanced NSCLC patients with brain metastasis. Methods Forty-four consecutive NSCLC patients with brain metastases were treated with gefitinib, which was administered orally at daily dose of 250 mg. Of these patients, 30 had been treated with WBRT and 42 received chemotherapy one month before enrolled into the study. Results Partial response （PR） was observed in 14 patients （31. 8%） , stable disease （SD） in 21 （47. 7% ） with an overall disease control rate of 79. 5%. Median progression-free survival（PFS） was 9 months and median overall survival （OS） was 13. 0 months. The difference in disease control rate between the patients who had previous WBRT and those without was not significant（P =0.566）. The toxicity is mild and tolerable. Conclusion Our data shows that Cefitinib is safe and may be effective on brain metastasis, which may become an alternative treatment option for the patient with advanced NSCLC.

关 键 词：脑肿瘤 肿瘤转移 吉非替尼 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R739.4[医药卫生—临床医学]